NeOnc Sets FDA Meeting to Discuss NEO212 Development Pathway

Event summary

NeOnc scheduled an FDA End-of-Phase 1 meeting for November 17, 2026, to discuss NEO212 clinical development.
Phase 1 dose escalation was discontinued at 810 mg due to toxicity; 610 mg selected as recommended Phase 2 dose.
NEO212 showed encouraging clinical activity in recurrent glioblastoma and lung cancer brain metastases.
Company seeks FDA feedback on trial design, endpoints, and potential accelerated approval pathway.

The big picture

NeOnc's meeting with the FDA marks a critical juncture in the development of NEO212, an oral conjugate for CNS cancers. The discussion comes amid growing interest in targeted therapies for high-grade gliomas and brain metastases, where treatment options remain limited. The outcome could shape the company's path to potential approval and its competitive positioning in the oncology space.

What we're watching

Regulatory Feedback: Whether FDA's input will align with NeOnc's proposed trial design and accelerated approval strategy.
Clinical Validation: The pace at which NEO212 can demonstrate efficacy in larger Phase 2 studies.
Development Strategy: How NeOnc will adjust its plans based on FDA's guidance for NEO212's next stages.